Lv5
1010 积分 2022-08-30 加入
Immune Checkpoint Inhibitor‐Induced Myositis, Myocarditis, Myasthenia Gravis, and Autonomic Neuropathy Successfully Treated With Rituximab
2天前
已完结
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
3天前
已完结
Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature
18天前
已关闭
Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab
18天前
已完结
Obinutuzumab is effective for the treatment of frequently-relapsing/steroid-dependent minimal change disease in adults
18天前
已完结
Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study
18天前
已完结
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry
24天前
已完结
Reconsidering Obinutuzumab: A Review of Type II Anti‐ CD20 Antibodies in Immunological Disorders of the Nervous System
24天前
已完结
Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome
1个月前
已完结
[Expert consensus on the treatment of chronic kidney disease with tuberculosis (2022 version)]
1个月前
已完结
皖公网安备34019202002308
